openPR Logo
Press release

Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017

10-16-2017 09:10 AM CET | Health & Medicine

Press release from: Arizton Advisory & Intelligence

Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017

Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017

“Tumor Necrosis Factor Alpha (TNF-a) Inhibitors-Pipeline Insights 2017″, report provides comprehensive analysis of TNF-a drug candidates currently undergoing clinical trials. The report covers detailed drug profiles of potential TNF-a inhibitors across various clinical development phases including – discovery, pre-clinical, IND, Phase I, Phase II, Phase III and Pre-registration. Report also includes the pipeline products’ clinical trial data along with information on other development activities including technology, licensing, collaborations, acquisitions, funding, patent and USFDA & EMA designations. Report also assesses the pipeline TNF-a inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides detailed information on the discontinued and dormant drugs.

View details: https://www.arizton.com/reports/pharma-pipeline-analysis/tumor-necrosis-factor-alpha-tnf-a-inhibitors-pipeline-insights

Key players developing potential TNF-a drug candidates have been profiled in the report. Each of the company profile provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Scope

Report provides in-depth insights on active TNF-a inhibitors pipeline drug candidates

Extensive pipeline product coverage with demarcation by various stages of development from NDA filings to discovery.

Provides pipeline assessment by monotherapy, combination therapy products and route of administration

Provides comparative analysis of key marketed and pipeline TNF-a inhibitors
Coverage of detailed pipeline drug profiles which includes product description, chemical information, MOA, licensors & collaborators, development partner

The report analyses key players involved in clinical research and development of the TNF-a inhibitors

Coverage of key news related to TNF-a inhibitors including major mergers and acquisitions and all product development updates such as clinical trial progression updates, regulatory updates

Related Reports

1) Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/histone-deacetylase-hdac-inhibitors-pipeline-insights

2) AKT Inhibitors - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/akt-inhibitors-pipeline

About Arizton
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017 here

News-ID: 774108 • Views:

More Releases for Inhibitors

Thymidine Phosphorylase Inhibitors Market - Breaking the Cycle: Angiogenesis Inh …
Newark, New Castle, USA: The "Thymidine Phosphorylase Inhibitors Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Thymidine Phosphorylase Inhibitors Market: https://www.growthplusreports.com/report/thymidine-phosphorylase-inhibitors-market/8826 This latest report researches the industry structure,
CGRP Inhibitors Market - Break Free from Migraine: CGRP Inhibitors Redefining Re …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global CGRP Inhibitors Market. CGRP Inhibitors Market: https://www.growthplusreports.com/report/cgrp-inhibitors-market/9155 The CGRP Inhibitors Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy.
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy 1.1 Overview 1.2 History- From Tragedy to Breakthrough Major Immune Checkpoints Proteins 2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development 2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development Mechanism of Action of Immune Checkpoint Inhibitors 3.1 Cytotoxic T lymphocyte Antigen-4
Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …
Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity. The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab